NCT04553133 2025-08-28
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04606446 2025-08-13
KAT6
Pfizer
Phase 1 Recruiting
NCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02349633 2021-06-10
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Pfizer
Phase 1/2 Terminated